Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01482221 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 542
- Enrollment target
NCT01482221: Completed Phase 2 study, sponsored by AstraZeneca.
NCT01482221 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 542 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (308% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01482221, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 542 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect and safety of AZD6765 in patients with major depressive disorder who exhibit inadequate response to antidepressants. AZD6765 is a channel blocker of the N-methyl-D-aspartate (NMDA) class of glutamate receptors.
Primary Outcome
A 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.
Interventions
- DRUG Placebo
- DRUG AZD6765 iv
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 542 participants |
| Start Date | 2011-12-16 |
| Est. Completion | 2013-08-26 |
| Phase | Phase 2 |
What the finished NCT01482221 record still lists
NCT01482221 is an interventional study that assigns participants to a tested intervention. The registered 542 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (308% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01482221 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01482221 about?
NCT01482221 is a clinical study titled "A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder". The purpose of this study is to assess the effect and safety of AZD6765 in patients with major depressive disorder who exhibit inadequate response to antidepressants. AZD6765 is a channel blocker of the N-methyl-D-aspartate (NMDA) class of glutamate receptors.
What is the current status of trial NCT01482221?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 542 participants. The study started on 2011-12-16. Estimated completion is 2013-08-26.
What interventions are being tested in trial NCT01482221?
The interventions under investigation include: Placebo (DRUG), AZD6765 iv (DRUG).
Who is sponsoring clinical trial NCT01482221?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01482221's enrollment target sits among peer trials
542 62nd of 2000 higher than 1,939 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04929223 · 542 participants · Phase 1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- NCT05584670 · 542 participants · Phase 1
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
- NCT07294053 · 543 participants · NA
Sugary Drink Labeling Study
- NCT03127761 · 544 participants
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI